• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在疟疾疫苗临床试验中,RTS,S/AS02(A) 和 RTS,S/AS01(B) 对成年人中疟原虫基因型的影响。

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.

机构信息

Walter Reed Project, Kenya Medical Research Institute, Kisumu, Kenya.

出版信息

PLoS One. 2009 Nov 17;4(11):e7849. doi: 10.1371/journal.pone.0007849.

DOI:10.1371/journal.pone.0007849
PMID:19924281
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2773849/
Abstract

OBJECTIVE

RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast containing part of the circumsporozoite protein (CSP) sequence of 3D7 strain of Plasmodium falciparum linked to the hepatitis B surface antigen in a hybrid protein. The RTS,S antigen is formulated with GSK Biologicals' proprietary Adjuvant Systems AS02(A) or AS01(B). A recent trial of the RTS,S/AS02(A) and RTS,S/AS01(B) vaccines evaluated safety, immunogenicity and impact on the development of parasitemia of the two formulations. Parasite isolates from this study were used to determine the molecular impact of RTS,S/AS02(A) and RTS,S/AS01(B) on the multiplicity of infection (MOI) and the csp allelic characteristics of subsequent parasitemias.

DESIGN

The distribution of csp sequences and the MOI of the infecting strains were examined at baseline and in break-through infections from vaccinated individuals and from those receiving a non-malarial vaccine.

SETTING

The study was conducted in Kombewa District, western Kenya.

PARTICIPANTS

Semi-immune adults from the three study arms provided isolates at baseline and during break-through infections.

OUTCOME

Parasite isolates used for determining MOI and divergence of csp T cell-epitopes were 191 at baseline and 87 from break-through infections.

RESULTS

Grouping recipients of RTS,S/AS01(A) and RTS,S/AS02(B) together, vaccine recipients identified as parasite-positive by microscopy contained significantly fewer parasite genotypes than recipients of the rabies vaccine comparator (median in pooled RTS,S groups: 3 versus 4 in controls, P = 0.0313). When analyzed separately, parasitaemic individuals in the RTS,S/AS01(B) group, but not the RTS,S/AS02(A) group, were found to have significantly fewer genotypes than the comparator group. Two individual amino acids found in the vaccine construct (Q339 in Th2R and D371 in Th3R) were observed to differ in incidence between vaccine and comparator groups but in different directions; parasites harboring Q339 were less common among pooled RTS,S/AS vaccine recipients than among recipients of rabies vaccine, whereas parasites with D371 were more common among the RTS,S/AS groups.

CONCLUSIONS

It is concluded that both RTS,S/AS vaccines reduce multiplicity of infection. Our results do not support the hypothesis that RTS,S/AS vaccines elicit preferential effects against pfcsp alleles with sequence similarity to the 3D7 pfcsp sequence employed in the vaccine construct.

摘要

目的

RTS,S 是一种疟疾候选疫苗,它是一种在酵母中表达的重组蛋白,包含 3D7 株疟原虫环子孢子蛋白(CSP)序列的一部分,与乙型肝炎表面抗原在杂交蛋白中连接。RTS,S 抗原与葛兰素史克生物公司专有的佐剂系统 AS02(A)或 AS01(B)联合配制。最近对 RTS,S/AS02(A)和 RTS,S/AS01(B)疫苗的试验评估了两种配方的安全性、免疫原性和对寄生虫血症发展的影响。本研究中的寄生虫分离株用于确定 RTS,S/AS02(A)和 RTS,S/AS01(B)对感染株的多重感染(MOI)和随后寄生虫血症中 csp 等位基因特征的分子影响。

设计

在基线和接种个体的突破性感染以及接受非疟疾疫苗的个体的突破性感染中,检查 csp 序列的分布和感染株的 MOI。

地点

该研究在肯尼亚西部 Kombewa 区进行。

参与者

来自三个研究组的半免疫成年人在基线和突破性感染时提供分离物。

结果

用于确定 MOI 和 csp T 细胞表位差异的寄生虫分离物在基线时有 191 个,突破性感染时有 87 个。

结论

RTS,S/AS 疫苗均降低了感染的多重性。我们的结果不支持 RTS,S/AS 疫苗对与疫苗构建体中使用的 3D7 株 pfcsp 序列具有序列相似性的 pfcsp 等位基因产生优先作用的假设。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/3f012fedb5cd/pone.0007849.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/33d59c3daaef/pone.0007849.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/a8a8f3eb9931/pone.0007849.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/7cfd81df38cb/pone.0007849.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/3f012fedb5cd/pone.0007849.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/33d59c3daaef/pone.0007849.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/a8a8f3eb9931/pone.0007849.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/7cfd81df38cb/pone.0007849.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fad5/2773849/3f012fedb5cd/pone.0007849.g004.jpg

相似文献

1
Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.在疟疾疫苗临床试验中,RTS,S/AS02(A) 和 RTS,S/AS01(B) 对成年人中疟原虫基因型的影响。
PLoS One. 2009 Nov 17;4(11):e7849. doi: 10.1371/journal.pone.0007849.
2
Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.加纳儿童按照不同方案接种 RTS,S/AS02D 和 RTS,S/AS01E 疟疾候选疫苗的随机对照试验
PLoS One. 2009 Oct 2;4(10):e7302. doi: 10.1371/journal.pone.0007302.
3
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.一项 IIa 期、随机、双盲、安全性、免疫原性和疗效试验,评估用 AS02 佐剂配制的恶性疟原虫裂殖子表面蛋白 1 和 RTS,S 疫苗抗原在健康、无疟疾的成年人中的效果。
Vaccine. 2024 Apr 30;42(12):3066-3074. doi: 10.1016/j.vaccine.2024.03.072. Epub 2024 Apr 6.
4
Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.RTS,S/AS02 恶性疟原虫疟疾疫苗的保护效力并非菌株特异性的。
Am J Trop Med Hyg. 2003 Jan;68(1):97-101.
5
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.对RTS,S/AS01和RTS,S/AS02佐剂疫苗免疫反应的评估:疟疾初发成人的随机双盲研究。
Hum Vaccin Immunother. 2014;10(8):2211-9. doi: 10.4161/hv.29375.
6
Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.印度间日疟原虫环子孢子蛋白的遗传变异及其与 RTS,S 疟疾疫苗的相关性。
PLoS One. 2012;7(8):e43430. doi: 10.1371/journal.pone.0043430. Epub 2012 Aug 17.
7
Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).在冈比亚儿童中接种 RTS,S/AS01(E) 和 RTS,S/AS02(D) 疫苗诱导疟原虫特异性 CD4+ T 细胞和记忆 B 细胞
PLoS One. 2011 Apr 11;6(4):e18559. doi: 10.1371/journal.pone.0018559.
8
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.一项在加蓬儿童中评估 AS01 和 AS02 佐剂 RTS,S 疟疾疫苗候选物安全性和免疫原性的随机试验。
PLoS One. 2009 Oct 27;4(10):e7611. doi: 10.1371/journal.pone.0007611.
9
Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.RTS,S/AS01疟疾疫苗在世界卫生组织1期或2期HIV疾病婴幼儿中的安全性和免疫原性:一项随机、双盲、对照试验。
Lancet Infect Dis. 2016 Oct;16(10):1134-1144. doi: 10.1016/S1473-3099(16)30161-X. Epub 2016 Jul 7.
10
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.RTS,S/AS02疟疾疫苗对冈比亚半免疫成年男性恶性疟原虫感染的疗效:一项随机试验。
Lancet. 2001 Dec 8;358(9297):1927-34. doi: 10.1016/S0140-6736(01)06957-4.

引用本文的文献

1
The Walter Reed Project, Kisumu Field Station: Impact of Research on Malaria Policy, Management, and Prevention.沃尔特·里德项目,基苏木野外工作站:疟疾研究对政策、管理和预防的影响。
Am J Trop Med Hyg. 2024 Apr 23;110(6):1069-1079. doi: 10.4269/ajtmh.23-0115. Print 2024 Jun 5.
2
Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?将基因分型数据纳入疗效估算器能否提高疟疾疫苗早期临床试验的效率?
Malar J. 2023 Dec 19;22(1):383. doi: 10.1186/s12936-023-04802-0.
3
Malaria Genomics, Vaccine Development, and Microbiome.

本文引用的文献

1
Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.在高疟疾传播地区对成人进行RTS,S/AS02A和RTS,S/AS01B评估。
PLoS One. 2009 Jul 31;4(7):e6465. doi: 10.1371/journal.pone.0006465.
2
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.恶性疟原虫疟疾疫苗RTS,S/AS01B和RTS,S/AS02A在未感染疟疾成年人中的随机、双盲、2a期试验:安全性、有效性及保护的免疫相关因素
J Infect Dis. 2009 Aug 1;200(3):337-46. doi: 10.1086/600120.
3
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
疟疾基因组学、疫苗研发与微生物组
Pathogens. 2023 Aug 18;12(8):1061. doi: 10.3390/pathogens12081061.
4
Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson's disease.对多巴胺能神经元的发育和分化至关重要的基因在帕金森病中表达下调。
J Neural Transm (Vienna). 2023 Apr;130(4):495-512. doi: 10.1007/s00702-023-02604-x. Epub 2023 Feb 23.
5
Genetic polymorphism of circumsporozoite protein of Plasmodium falciparum among Chinese migrant workers returning from Africa to Henan Province.河南省归国农民工中恶性疟原虫环子孢子蛋白的遗传多态性。
Malar J. 2022 Aug 27;21(1):248. doi: 10.1186/s12936-022-04275-7.
6
Population genetic analysis of the Plasmodium falciparum circumsporozoite protein in two distinct ecological regions in Ghana.加纳两个不同生态区域恶性疟原虫环子孢子蛋白的群体遗传学分析。
Malar J. 2020 Nov 27;19(1):437. doi: 10.1186/s12936-020-03510-3.
7
Balancing selection and high genetic diversity of Plasmodium vivax circumsporozoite central region in parasites from Brazilian Amazon and Rio de Janeiro Atlantic Forest.巴西亚马逊和里约热内卢大西洋森林地区疟原虫环子孢子蛋白中央区的平衡选择和高遗传多样性。
PLoS One. 2020 Nov 9;15(11):e0241426. doi: 10.1371/journal.pone.0241426. eCollection 2020.
8
The Delay in the Licensing of Protozoal Vaccines: A Comparative History.原生动物疫苗的许可延迟:比较历史。
Front Immunol. 2020 Mar 6;11:204. doi: 10.3389/fimmu.2020.00204. eCollection 2020.
9
Genetic polymorphism of the N-terminal region in circumsporozoite surface protein of Plasmodium falciparum field isolates from Sudan.苏丹疟疾病例环子孢子蛋白 N 端区的遗传多态性。
Malar J. 2019 Oct 1;18(1):333. doi: 10.1186/s12936-019-2970-0.
10
RTS,S/AS01 vaccine (Mosquirix™): an overview.RTS,S/AS01疫苗(Mosquirix™)概述。
Hum Vaccin Immunother. 2020 Mar 3;16(3):480-489. doi: 10.1080/21645515.2019.1669415. Epub 2019 Oct 22.
RTS,S/AS02A疟疾疫苗在莫桑比克儿童中的长期安全性和有效性
J Infect Dis. 2009 Aug 1;200(3):329-36. doi: 10.1086/600119.
4
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.RTS,S/AS01E疫苗对5至17月龄儿童疟疾的疗效。
N Engl J Med. 2008 Dec 11;359(24):2521-32. doi: 10.1056/NEJMoa0807381. Epub 2008 Dec 8.
5
Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.RTS,S/AS02D疟疾疫苗在婴儿中的安全性和免疫原性。
N Engl J Med. 2008 Dec 11;359(24):2533-44. doi: 10.1056/NEJMoa0807773. Epub 2008 Dec 8.
6
Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.在沃尔特·里德陆军研究所,针对未感染疟疾的成年人,开展了疟疾疫苗RTS,S/AS02的0、1和3个月以及0、7和28天免疫接种计划的2a期试验。
Vaccine. 2008 Apr 24;26(18):2191-202. doi: 10.1016/j.vaccine.2008.02.048. Epub 2008 Mar 13.
7
Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.新型配方的RTS,S疫苗抗原诱导小鼠和猴子对恶性疟原虫环子孢子蛋白的T细胞反应增强。
Vaccine. 2008 Feb 20;26(8):1072-82. doi: 10.1016/j.vaccine.2007.12.018. Epub 2008 Jan 7.
8
Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites.冈比亚恶性疟原虫中 pfcrt 和 pfmdr1 等位基因的季节性携带表明耐氯喹寄生虫的适应性降低。
J Infect Dis. 2007 Dec 1;196(11):1613-9. doi: 10.1086/522154. Epub 2007 Oct 25.
9
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.RTS,S/AS02D候选疟疾疫苗在莫桑比克高流行地区婴儿中的安全性:一项双盲随机对照I/IIb期试验
Lancet. 2007 Nov 3;370(9598):1543-51. doi: 10.1016/S0140-6736(07)61542-6. Epub 2007 Oct 18.
10
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.在未感染过疟疾的成年人中进行的一项I/IIa期安全性、免疫原性和疗效桥接随机研究,该研究针对候选疟疾疫苗RTS,S/AS02A的液体和冻干制剂的两剂方案。
Vaccine. 2007 Jul 20;25(29):5359-66. doi: 10.1016/j.vaccine.2007.05.005. Epub 2007 May 30.